Henry Schein, Inc. (HSIC) Given Consensus Recommendation of “Hold” by Analysts
Henry Schein, Inc. (NASDAQ:HSIC) has received an average recommendation of “Hold” from the seventeen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $92.23.
Several analysts have recently issued reports on the stock. UBS AG reiterated a “buy” rating on shares of Henry Schein in a research note on Friday. Piper Jaffray Companies upgraded shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday. Credit Suisse Group reiterated a “hold” rating and issued a $87.50 target price on shares of Henry Schein in a research note on Tuesday, August 29th. Zacks Investment Research lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Northcoast Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Monday, August 7th.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/henry-schein-inc-hsic-given-consensus-recommendation-of-hold-by-analysts.html.
Shares of Henry Schein (HSIC) opened at 82.88 on Friday. Henry Schein has a 52 week low of $82.16 and a 52 week high of $186.99. The firm has a market cap of $6.55 billion, a PE ratio of 12.11 and a beta of 1.10. The firm has a 50-day moving average of $170.49 and a 200-day moving average of $175.55.
Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.86 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the business posted $0.82 EPS. The business’s revenue was up 6.4% compared to the same quarter last year. On average, analysts expect that Henry Schein will post $7.27 EPS for the current year.
In related news, SVP Paul Rose sold 2,126 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the transaction, the senior vice president now directly owns 17,841 shares of the company’s stock, valued at approximately $3,077,750.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.27% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. Waldron LP purchased a new stake in Henry Schein during the first quarter valued at about $286,000. Wells Fargo & Company MN lifted its holdings in Henry Schein by 14.1% during the first quarter. Wells Fargo & Company MN now owns 128,257 shares of the company’s stock valued at $21,799,000 after purchasing an additional 15,874 shares during the last quarter. First Trust Advisors LP lifted its holdings in Henry Schein by 0.6% during the first quarter. First Trust Advisors LP now owns 85,131 shares of the company’s stock valued at $14,470,000 after purchasing an additional 546 shares during the last quarter. Karp Capital Management Corp purchased a new stake in Henry Schein during the first quarter valued at about $7,401,000. Finally, Smith Salley & Associates lifted its holdings in Henry Schein by 10.9% during the first quarter. Smith Salley & Associates now owns 1,598 shares of the company’s stock valued at $272,000 after purchasing an additional 157 shares during the last quarter. 89.11% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.